Alex Zisson

Alex was a partner at Thomas, McNerney & Partners since its first fund was raised in 2002. Alex is currently a Managing Director at H.I.G. BioVentures. He currently serves on the board of directors for Clarus Therapeutics, Inc. Alex is a member of the Industry Advisory Board of the Children's Tumor Foundation and a board member of Advanced Medical Research Institute of Canada Development Corporation (AMRIC-DC), which is focused on economic development in northern Ontario. He is also an advisor for the Partnership Fund of NYC, which manages a bioaccelerator to advance local health care research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists female entrepreneurs. Prior to Thomas, McNerney, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. After the merger of Chase H&Q and JPMorgan, he became the firm's Health Care Strategist. He was named twice in The Wall Street Journal's All-Star Analysts Survey, including during his last year at JPMorgan, when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and 'home run' hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.